PE-22-28

What is PE-22-28?

PE-22-28 targets a mechanism for depression that no approved antidepressant touches: TREK-1 potassium channels. TREK-1 (TWIK-related K+ channel 1) is a background potassium channel expressed in neurons throughout the brain's limbic system. When TREK-1 activity is too high, neurons are hyperpolarized and underactive — a state associated with depression. TREK-1 knockout mice are resistant to depression-like behavior and have elevated monoamine levels. PE-22-28 blocks TREK-1, restoring normal neuronal excitability.

The excitement comes from two things: the mechanism is completely novel — no approved drug works this way — and the onset appears faster than conventional antidepressants in preclinical models. SSRIs require 4–8 weeks to produce antidepressant effects. PE-22-28 produced antidepressant-like behavior in mouse models within 24–48 hours, with effects comparable to fluoxetine at 3 weeks achieved much faster.

PE-22-28 also upregulates BDNF in the hippocampus — the same downstream effect that accounts for antidepressants' long-term efficacy, but achieved faster and through a different upstream pathway. The honest picture: compelling preclinical story, zero human data. Users are extrapolating from rodent studies with uncharacterized human risk.

How it works

TREK-1 Channel Inhibition

TREK-1 is a two-pore domain potassium channel (K2P) contributing to background potassium conductance in neurons. When open, potassium flows out of the neuron, hyperpolarizing the membrane and reducing firing. In depression models, TREK-1 overactivity produces a hypoactive limbic system. PE-22-28 (derived from spadin, a natural TREK-1 antagonist in CSF) blocks TREK-1, shifting neuronal excitability toward a more active state and increasing serotonin, noradrenaline, and dopamine activity.

Monoamine Elevation — Same End Result, Different Upstream

TREK-1 inhibition increases the firing rate of serotonergic neurons in the raphe nucleus and noradrenergic neurons in the locus coeruleus — elevating serotonin and noradrenaline in limbic regions. This is the same end result that SSRIs and SNRIs produce, but through a completely different upstream mechanism. PE-22-28 doesn't block reuptake transporters — it increases the firing of the neurons that release monoamines in the first place.

BDNF Upregulation and Neuroplasticity

PE-22-28 increases BDNF expression in the hippocampus faster than conventional antidepressants in preclinical models. BDNF drives neurogenesis, synaptic plasticity, and dendritic spine formation — the structural brain changes underlying recovery from depression. The monoamine hypothesis has been challenged by the observation that SSRIs raise serotonin within hours but take weeks to treat depression — suggesting downstream neuroplasticity (BDNF, neurogenesis) is the actual therapeutic mechanism. PE-22-28's faster BDNF induction via TREK-1 inhibition may represent a more direct path to these changes.

What the research shows

Community knowledge

PE-22-28 has a small community primarily among people researching novel antidepressant mechanisms who have followed the TREK-1 literature. Reported effects: mood improvement described as cleaner and faster than oral antidepressants, anxiolytic effect alongside mood improvement, and no sexual side effects — the most commonly cited advantage over SSRIs. Response is highly variable, consistent with zero human dose-finding data. Often stacked with Selank (anxiolytic) or Semax (BDNF/cognition) in the mood peptide stack.